Antibody targeting of E3 ubiquitin ligases for receptor degradation

Most current therapies that target plasma membrane receptors function by antagonizing ligand binding or enzymatic activities. However, typical mammalian proteins comprise multiple domains that execute discrete but coordinated activities. Thus, inhibition of one domain often incompletely suppresses t...

Descripción completa

Detalles Bibliográficos
Autores principales: Marei, Hadir, Tsai, Wen-Ting K., Kee, Yee-Seir, Ruiz, Karen, He, Jieyan, Cox, Chris, Sun, Tao, Penikalapati, Sai, Dwivedi, Pankaj, Choi, Meena, Kan, David, Saenz-Lopez, Pablo, Dorighi, Kristel, Zhang, Pamela, Kschonsak, Yvonne T., Kljavin, Noelyn, Amin, Dhara, Kim, Ingrid, Mancini, Andrew G., Nguyen, Thao, Wang, Chunling, Janezic, Eric, Doan, Alexander, Mai, Elaine, Xi, Hongkang, Gu, Chen, Heinlein, Melanie, Biehs, Brian, Wu, Jia, Lehoux, Isabelle, Harris, Seth, Comps-Agrar, Laetitia, Seshasayee, Dhaya, de Sauvage, Frederic J., Grimmer, Matthew, Li, Jing, Agard, Nicholas J., de Sousa e Melo, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534761/
https://www.ncbi.nlm.nih.gov/pubmed/36131013
http://dx.doi.org/10.1038/s41586-022-05235-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534761/
https://www.ncbi.nlm.nih.gov/pubmed/36131013
http://dx.doi.org/10.1038/s41586-022-05235-6

Ejemplares similares